Chronic Obstructive Pulmonary DiseaseNCT07762573
Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study
An observational study of Chronic Obstructive Pulmonary Disease, run by Nanfang Hospital, Southern Medical University at 1 site in China.
Trial summary
To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD. Read more about this study
- Who is it for?
- Ages 30 to 85 years
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease
- How many people
- 2,500 participants
- Where
- 1 siteChina
- Study dates
- 3 Aug 2026to 30 Jan 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms, including dyspnea, cough, and sputum production. These symptoms result from airway abnormalities, such as bronchitis or bronchiolitis, and/or alveolar abnormalities, such as emphysema, that cause persistent and often progressive airflow obstruction.
Who may be able to join
- Aged 30-85 years.
- Male or female.
- Patients who underwent pulmonary function testing and dynamic chest radiography at the hospital.
Who cannot join
- Incomplete medical records.
- Considered unsuitable for inclusion in the study at the investigator's discretion.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510400
Laiyu Liu, Professor, +86 13632102245, liulaiyu@sina.com
About this study
To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD.
Read the detailed description
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Approximately 100 million people in China have COPD, yet the early diagnosis rate remains below 13%. This multicenter retrospective study will collect previously acquired dynamic chest radiography (DCR) images, pulmonary function test results, chest computed tomography images, symptom scores, clinical data, and follow-up outcomes from participating centers. A standardized multicenter retrospective DCR-COPD database will be established to systematically evaluate the utility of DCR-derived parameters for characterizing dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of COPD progression. The study will also provide a foundation for model development and subsequent prospective multicenter validation.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Keywords
- Chronic obstructive pulmonary disease, Dynamic Chest Radiography
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COPD group | any patient who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and/or a history of exposure to disease risk factors, Pulmonary function examination indicated that FEV1/FVC <0.7 after bronchodilator was used to confirm COPD. | |
| PRISM group | After bronchial dilation, FEV1/FVC was ≥0.70, and FEV1%PRED was <80%. | |
| Smoking exposure groups | Smoking history of 10 years, or without COPD, pulmonary function of COPD diagnosis standard. | |
| Normal control group | Never-smokers without airflow limitation and with normal pulmonary function. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exacerbation/respiratory history and event
Measurement of disease control and burden
Measured: At Baseline
FEV1 %
Measurement of lung function
Measured: At Baseline
FEV1 /FVC
Measurement of lung function
Measured: At Baseline
Emphysema
Measurement of chest CT
Measured: At Baseline
diaphragm movement
Measurement of Dynamic chest radiograph
Measured: At Baseline
lung field area
Measurement of Dynamic chest radiograph
Measured: At Baseline
lung field area change rate
Measurement of Dynamic chest radiograph
Measured: At Baseline
CAT
Measurement of questionnaires
Measured: At Baseline
SGRQ
Measurement of questionnaires
Measured: At Baseline
mMRC
Measurement of questionnaires
Measured: At Baseline
Smoking history and status
Risk factors of COPD development or lung function decline
Measured: At Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2026
- Study start3 Aug 2026
- Primary completion30 Dec 2029 (estimated)
- Study completion30 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Obstructive Pulmonary DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- The First Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital
- Responsible party
- Sponsor
- Investigators
- Laiyu Liu, professor, Study chair, Nanfang Hospital, Southern Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07762573
- Sponsor's protocol ID
- NFEC-2026-570
- Other IDs
- 2025CR003
- Status last verified
- Aug 2026
- First submitted
- 9 Aug 2026
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study
- ClinicalTrials.gov ID
- NCT07762573
- Acronym / sponsor ID
- NFEC-2026-570
- Conditions
- Chronic Obstructive Pulmonary Disease
- Keywords
- Chronic obstructive pulmonary disease, Dynamic Chest Radiography
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,500 participants (estimated)
- Lead sponsor
- Nanfang Hospital, Southern Medical UniversityUniversity, hospital or other
- Collaborators
- The First Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital
- Study start
- 3 Aug 2026 (actual)
- Primary completion
- 30 Dec 2029 (estimated)
- Study completion
- 30 Jan 2030 (estimated)
- First posted
- 13 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD.
Detailed description
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Approximately 100 million people in China have COPD, yet the early diagnosis rate remains below 13%. This multicenter retrospective study will collect previously acquired dynamic chest radiography (DCR) images, pulmonary function test results, chest computed tomography images, symptom scores, clinical data, and follow-up outcomes from participating centers. A standardized multicenter retrospective DCR-COPD database will be established to systematically evaluate the utility of DCR-derived parameters for characterizing dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of COPD progression. The study will also provide a foundation for model development and subsequent prospective multicenter validation.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| COPD group | – | –any patient who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and/or a history of exposure to disease risk factors, Pulmonary function examination indicated that FEV1/FVC <0.7 after bronchodilator was used to confirm COPD. |
| PRISM group | – | –After bronchial dilation, FEV1/FVC was ≥0.70, and FEV1%PRED was <80%. |
| Smoking exposure groups | – | –Smoking history of 10 years, or without COPD, pulmonary function of COPD diagnosis standard. |
| Normal control group | – | –Never-smokers without airflow limitation and with normal pulmonary function. |
Who may qualify
- Ages
- 30 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms, including dyspnea, cough, and sputum production. These symptoms result from airway abnormalities, such as bronchitis or bronchiolitis, and/or alveolar abnormalities, such as emphysema, that cause persistent and often progressive airflow obstruction.
Key inclusion criteria (3 listed)
- Aged 30-85 years.
- Male or female.
- Patients who underwent pulmonary function testing and dynamic chest radiography at the hospital.
Key exclusion criteria (2 listed)
- Incomplete medical records.
- Considered unsuitable for inclusion in the study at the investigator's discretion.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Exacerbation/respiratory history and event
Time frame: At Baseline
Measurement of disease control and burden
FEV1 %
Time frame: At Baseline
Measurement of lung function
FEV1 /FVC
Time frame: At Baseline
Measurement of lung function
Emphysema
Time frame: At Baseline
Measurement of chest CT
diaphragm movement
Time frame: At Baseline
Measurement of Dynamic chest radiograph
lung field area
Time frame: At Baseline
Measurement of Dynamic chest radiograph
lung field area change rate
Time frame: At Baseline
Measurement of Dynamic chest radiograph
CAT
Time frame: At Baseline
Measurement of questionnaires
SGRQ
Time frame: At Baseline
Measurement of questionnaires
mMRC
Time frame: At Baseline
Measurement of questionnaires
Smoking history and status
Time frame: At Baseline
Risk factors of COPD development or lung function decline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
Related trials for Chronic Obstructive Pulmonary Disease
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
Not yet recruiting
Impact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway.
Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive
Not yet recruitingPhase 3
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 2
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
COPD
Not yet recruitingObservational study
Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)
Pulmonary Disease, Chronic Obstructive (COPD), Hypercapnia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Laiyu Liu, professor study chair
Nanfang Hospital, Southern Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Obstructive Pulmonary Disease, run by Nanfang Hospital, Southern Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Laiyu Liu, Professor (+86 13632102245, liulaiyu@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exacerbation/respiratory history and event (time frame: At Baseline). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026; AzTrials last refreshed its copy on 31 Oct 2026.